Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate atherosclerosis. The effects of atorvastatin (40 mg/day) and micronised fenofibrate (200 mg/day) on the kinetics of apoAI and apoB were investigated in a controlled cross-over trial of 11 dyslipidemic men with the metabolic syndrome. ApoAI and apoB kinetics were studied following intravenous d(3)-leucine administration using gas-chromatography mass spectrometry with data analyzed by compartmental modeling. Compared with placebo, atorvastatin significantly decreased (P < 0.001) plasma concentrations of cholesterol, triglyceride, LDL cholesterol, VLDL apoB, intermediate-density lipoprotein (IDL) apoB, and LDL apoB. Fenofibrate significantly decreased (P < 0.001) plasma triglyceride and VLDL apoB and elevated HDL(2) cholesterol (P < 0.001), HDL(3) cholesterol (P < 0.01), apoAI (P = 0.01), and apoAII (P < 0.001) concentrations, but it did not significantly alter LDL cholesterol. Atorvastatin significantly increased (P < 0.002) the fractional catabolic rate (FCR) of VLDL apoB, IDL apoB, and LDL apoB but did not affect the production of apoB in any lipoprotein fraction or in the turnover of apoAI. Fenofibrate significantly increased (P < 0.01) the FCR of VLDL, IDL, and LDL apoB but did not affect the production of VLDL apoB. Relative to placebo and atorvastatin, fenofibrate significantly increased the production (P < 0.001) and FCR (P = 0.016) of apoAI. Both agents significantly lowered plasma triglycerides and apoCIII concentrations, but only atorvastatin significantly lowered (P < 0.001) plasma cholesteryl ester transfer protein activity. Neither treatment altered insulin resistance. In conclusion, these differential effects of atorvastatin and fenofibrate on apoAI and apoB kinetics support the use of combination therapy for optimally regulating dyslipoproteinemia in the metabolic syndrome.

[1]  G. Watts,et al.  Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. , 2002, Metabolism: clinical and experimental.

[2]  P Hugh R Barrett,et al.  Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. , 2002, Diabetes.

[3]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[4]  B. Staels,et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.

[5]  M. Krempf,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society In Vivo Evidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subje , 2022 .

[6]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[7]  D. Le Roith,et al.  Recent advances in our understanding of insulin action and insulin resistance. , 2001, Diabetes care.

[8]  P. Gambert,et al.  Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. , 2000, Atherosclerosis.

[9]  H. Ginsberg.  Insulin resistance and cardiovascular disease. , 2000, The Journal of clinical investigation.

[10]  G. Watts,et al.  Fibrates, dyslipoproteinaemia and cardiovascular disease. , 1999, Current opinion in lipidology.

[11]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[12]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[13]  G. Watts,et al.  Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  C. Packard.  Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. , 1999, Current opinion in lipidology.

[15]  B. Maisch,et al.  Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. , 1999, Atherosclerosis.

[16]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[17]  M. Hanefeld,et al.  In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. , 1998, Diabetes.

[18]  C. Aguilar-Salinas,et al.  Metabolic modes of action of the statins in the hyperlipoproteinemias. , 1998, Atherosclerosis.

[19]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[20]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.

[21]  P. Durrington,et al.  Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. , 1998, Atherosclerosis.

[22]  S. Grundy,et al.  Statin trials and goals of cholesterol-lowering therapy. , 1998, Circulation.

[23]  J. Burnett,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. , 1997, Current opinion in lipidology.

[24]  G. Lewis.  Fatty acid regulation of very low density lipoprotein production. , 1997, Current opinion in lipidology.

[25]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[26]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[27]  E. Bruckert,et al.  Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[28]  T. R. Hennessy,et al.  Acute Hyperinsulinemia Decreases the Hepatic Secretion of Very-Low-Density Lipoprotein Apolipoprotein B-100 in NIDDM , 1995, Diabetes.

[29]  J. Auwerx,et al.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.

[30]  J. Bar-Tana,et al.  Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.

[31]  D. Rader,et al.  Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[32]  S. Eisenberg,et al.  Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  C. Packard,et al.  Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  C. Packard,et al.  Effects of simvastatin on apoB metabolism and LDL subfraction distribution. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  Y. Arad,et al.  Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. , 1990, Journal of lipid research.

[36]  C. Packard,et al.  Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. , 1986, Journal of lipid research.

[37]  E. Stange,et al.  Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. , 1985, Atherosclerosis.

[38]  P. Gartside,et al.  Mechanism of action of gemfibrozil on lipoprotein metabolism. , 1985, The Journal of clinical investigation.

[39]  C. Malmendier,et al.  Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. , 1985, Atherosclerosis.

[40]  H. G. Morgan,et al.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. , 1984, The Journal of clinical investigation.

[41]  S. Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. , 1983, Atherosclerosis. Supplements.

[42]  C. Packard,et al.  Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. , 1982, Atherosclerosis.

[43]  K. Parhofer,et al.  Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. , 2001, The American journal of cardiology.

[44]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[45]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[46]  M. Farnier,et al.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[47]  J. Ordovás,et al.  Metabolism of apolipoproteins A-I, A-II, and A-IV. , 1986, Methods in enzymology.

[48]  H. Brewer,et al.  Metabolism of human apolipoproteins A-I and A-II: compartmental models. , 1983, Journal of lipid research.